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With the ligands 4-phenyl-1-(furan-2-carbaldehyde)thiosemicarbazone, HTSC1, (1), 4-phenyl-1-
(5′-phenyl-furan-2-carbaldehyde)thiosemicarbazone, HTSC2 (2), o-methoxy-benzaldehydethiosemi-
carbazone, HTSC3 (3), and o-cyano-benzaldehydethiosemicarbazone, HTSC4 (4), the corresponding
palladium(II) complexes, Pd(TSC1)2 (5), Pd(TSC2)2 (6), Pd(TSC3)2 (7), and Pd(TSC4)2 (8) were
synthesized and characterized by elemental analysis and spectroscopic techniques. The crystal struc-
ture of Pd(TSC3)2 (7) was determined by single-crystal X-ray diffraction. Complex 7 shows a square-
planar geometry, where two deprotonated ligands are coordinated to the PdII center through the ni-
trogen and sulfur atoms in a trans arrangement. In vitro antitumor studies against different human
tumor cell lines have revealed that the palladium(II) complexes 5– 8 are more cytotoxic (IC50 values
in the range of 0.21 – 3.79 µM) than their corresponding ligands (1 – 4) (> 60 µM). These results
indicate that the antiproliferative activity is enhanced when thiosemicarbazone ligands are coordi-
nated to the metal. Among the studied palladium(II) complexes, 8 exhibits high antitumor activity on
K562 chronic myelogenous leukemia cells with a low value of the inhibitory concentration (IC50 =
0.21 µM).
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Introduction
The interest to find new compounds derived from
thiosemicarbazones and their transition metal com-
plexes has increased because these compounds possess
a wide variety of biological activities as antiviral, an-
timicrobial, anticancer, and antitumor agents [1 – 7].
Reports indicate that the in vitro antitumor activ-
ity against mammalian cells of chelating agents de-
rived from (N,N,S) heterocyclic thiosemicarbazones
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is due to the inhibition of the ribonucleotide reduc-
tase enzyme, which is responsible for the synthe-
sis of DNA precursors [8, 9]. The nature of the het-
eroatomic ring and the presence of the imine group
(-N=CH-) are important factors in the inhibitory ac-
tion against tumor cell growth [10]. Also, the cobalt,
nickel, zinc, chromium, and manganese complexes
with 1-(2-furanthiocarba)-3-thiosemicarbazide (S,S)
and furan-2-carbaldehyde thiosemicarbazone (N,S)
ligands present antitumor activity in vitro and in
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Scheme 1. Synthesis of the ligands
derived from furan-2-carbaldehyde and
benzaldehyde thiosemicarbazone.
Scheme 2. Synthesis of the palladium(II)
bis-chelate complexes of furan-2-carb-
aldehyde and benzaldehyde thiosemi-
carbazone.
vivo against several mice and human tumor cell lines
[11, 12]. On the other hand, the square-planar palla-
dium(II) and platinum(II) complexes M(L)Cl and ML2
with (N,N,S) ligands derived from 2-formyl and 2-
acetyl pyridine thiosemicarbazone show high antipro-
liferative activity in vitro and in vivo against differ-
ent human cancer cell lines and P388 mouse leukemia
cells, respectively [13, 14]. Moreover, the octahe-
dral nickel(II) complexes with phenanthrenequinone
and 1,2-naphthoquinone thiosemicarbazone (O,N,S) of
ML2 type exhibit high cytotoxicity in vitro against
the T47D and MCF-7 human breast cancer cell lines
[15, 16]. Recently, in vitro studies of the platinum(II)
and palladium(II) bis-chelate complexes with ben-
zaldehyde thiosemicarbazone derivatives against dif-
ferent human tumor cell lines showed that these metal
complexes are more cytotoxic than their respective
ligands [17]. Probably, the high cytotoxicity of these
square-planar palladium(II) complexes may be related
to the intercalation between pairs of DNA bases, or to
the breaking of DNA strands [18, 19].
The present work describes the synthesis, char-
acterization and antitumor activity of palladium(II)
bis-chelate complexes of the type Pd(TSC1−4)2 (5 – 8)








The ligands HTSC1−2 (1, 2) derived from furan-
2-carbaldehyde thiosemicarbazones, and the ligands
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HTSC3−4 (3, 4) derived from benzaldehyde thiosemi-
carbazone were prepared according to the literature
[17, 20, 21] as shown in Scheme 1.
The ligands were obtained in good yields (62 –
90 %) and characterized by elemental analysis and IR,
and 1H and 13C NMR spectroscopy. The palladium(II)
complexes were obtained in satisfactory yields (48 –
66 %) as shown in Scheme 2 and characterized by IR
and 1H and 13C NMR spectroscopy.
Analytical and spectroscopic data obtained for
the thiosemicarbazone ligands and their palladium(II)
complexes are in agreement with the proposed struc-
tures.
The complex Pd(TSC3)2 (7) was recrystallized from
an acetone solution, and single crystals suitable for the
structure determination by X-ray diffraction were ob-
tained.
Infrared spectra
The broad ν(N-H) bands of the -NH group observed
for the ligands at 3132 – 3292 cm−1 have disappeared
in the spectra of the corresponding complexes, indi-
cating the deprotonation of the NH-CS group. The
strong ν(C=N) bands of the thiosemicarbazones at
1600 – 1620 cm−1 are shifted in the spectra of the com-
plexes by about 15 – 25 cm−1 towards lower frequen-
cies, indicating coordination of the azomethine nitro-
gen atoms [22 – 24]. All ligands show medium bands
in the 854 – 950 cm−1 range, ascribed to ν(C=S) vi-
brations [25, 26]. These absorption bands are shifted
by 27 – 45 cm−1 towards lower frequencies for the
palladium(II) complexes, suggesting coordination of
the thiocarbonyl sulfur atoms [17]. These results in-
dicate that the thiosemicarbazone ligands are coordi-
nated bidentately to the palladium(II) ion through the
nitrogen and sulfur atoms.
NMR spectra
The chemical shift (δ ) data were extracted from the
1H NMR and 13C NMR spectra of the ligands and their
metal complexes recorded in deuterated dimethylsul-
foxide. In the 1H NMR spectra of the ligands, the
=N-NH protons were observed as singlets at δ =
11.42 – 11.97, while on complexation these signals
disappeared, thus indicating the deprotonation of the
=N-NH group. For all ligands, the signals of the
HC=N protons appear as singlets at δ = 8.08 – 8.41
[17, 26]. In the spectra of the complexes, these sig-
nals are shifted by 0.07 – 0.21 ppm upfield for the
Pd(TSC1−2)2 compounds (5, 6), while for Pd(TSC3)2
(7) and Pd(TSC4)2 (8) they are shifted by 0.64 ppm up-
field and 0.62 ppm downfield, respectively. These re-
sults confirm the coordination of the imine nitrogen to
the metal center [17, 24, 27, 28]. The NHPh aromatic
proton signals of the HTSC1 (1) and HTSC2 (2) lig-
ands appear at δ = 7.18 – 7.83, and the resonance lines
found correspond to the calculated multiplicity. The
resonance lines of the protons corresponding to the fu-
ran ring were observed at δ = 6.65 – 7.21, in agree-
ment with the chemical shifts found for other ligands
derived from furan-2-carbaldehyde thiosemicarbazone
[20, 24, 26]. For the ligands HTSC3 (3) and HTSC4 (4)
the aromatic proton signals are affected by the pres-
ence of the methoxy and cyano substituents at the or-
tho position of the phenyl moiety. These signals are
shifted upfield for the protons in the meta (0.40 ppm)
and para (0.04 ppm) positions for the TSC3(3) ligand,
while for the TSC4 ligand (4) the aromatic proton sig-
nals are shifted downfield for the meta (0.39 ppm) and
para (0.15 ppm) positions, relative to the unsubstituted
phenyl moiety [17]. The resonance signals of the furan
and phenyl protons in all ligands do not suffer rele-
vant changes in the chemical shifts for the complexes.
The NH2 protons of the thioamide group in the lig-
ands HTSC3 (3) and HTSC4 (4) show doublets in the
range of δ = 7.93 – 8.14 and δ = 7.95 – 8.47, respec-
tively, which are attributed to the restricted rotation of
the -NH2 group around the C–N bond, due to the delo-
calization of the lone pair on the NH2 nitrogen [17].
In the 13CNMR spectra, the carbon signals of the
HC=N group appear at δ = 132.47 – 137.93. These re-
sults are similar to the chemical shifts found for the lig-
ands furan-2-carboxaldehydethiosemicarbazone and
m-cyanobenzaldehydethiosemicarbazone (δ = 132.56
and 139.66, respectively) [17, 20]. The C=S signals
observed at δ = 175.64 – 178.64 are characteristic for
this thiocarbonyl group in all the ligands. For the lig-
ands HTSC1 (1) and HTSC2 (2) the resonance lines of
the furan carbons appear at δ = 108.54 – 154.83, and
these chemical shifts are in agreement with those found
for other thiosemicarbazone ligands [29 – 31]. For the
ligands HTSC3 (3) and HTSC4 (4) the aromatic car-
bons are observed at δ = 109.57 – 157.76.
The 13C NMR spectrum of the complex Pd(TSC3)2
(7) shows a duplication of the signals for the methoxy
(δ = 56.03, 55.59), aryl (δ = 158.47 – 111.02), imine
(δ = 148.59, 143.99) and thiocarbonyl (δ = 176.81,
174.51) groups, while for the complex Pd(TSC4)2 (8)
this duplication of the signals appears for the cyano
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(δ = 119.69, 118.06) and aryl (δ = 153.13 – 126.95)
groups. These results could indicate that the cis- and
trans-isomers of Pd(TSC3)2 (7) and Pd(TSC4)2 (8) co-
exist in DMSO solution.
Structural data
The complex Pd(TSC3)2 (7) crystallizes in the
monoclinic space group C2/c with 4 molecules in the
unit cell, as a bis-chelate with Ci molecular symmetry
(Fig. 1).
The deprotonated ligand coordinates bidentately
through the S and N atoms. The coordination of the
Pd atom is square planar with a trans arrangement of
the coordinating atoms. The coordination leads to a
lengthening of the S1–C1 bond and to a shortening of
the C1–N2 bond. Selected bond lengths and angles are
listed in Table 1.
Strong hydrogen bonds between the hydrogen atoms
of the amino groups and the N2 atoms of the chelate
rings lead to a one-dimensional chain structure, re-
lated by centers of inversion (Fig. 2). The bond pa-
rameters for this hydrogen bonds are: N1–H2N 0.81 Å,
N2· · ·H2N 2.25(2) Å, N1· · ·N2 3.050(2) Å.
Fig. 1. Molecular structure of Pd(TSC3)2 (7) in the crystal.
The displacement ellipsoids are drawn at the 50 % probabil-
ity level, hydrogen atoms with arbitrary radii.
Fig. 2. One-dimensional chain structure of Pd(TSC3)2 (7) in
the crystal.
Table 1. Selected bond lengths (Å) and angles (deg) for
Pd(TSC3)2 (7).
Distances Angles
Pd1–S1 2.2922(5) S1–Pd1–N3 82.96(4)
Pd1–N3 2.026(1) Pd1–N3–N2 120.2(1)
N2–N3 1.391(2) N3–N2–C1 113.5(1)
C1–N2 1.312(2) N2–C1–S1 124.8(1)
C1–S1 1.745(2) N2–C1–N1 118.3(2)
C1–N1 1.339(2) N1–C1–S1 116.9(1)
Antitumor evaluation
The ligands derived from the thiosemicarbazone
molecule have IC50 values in the range of 60 –
100 µM (micromolar concentration inhibiting 50 %
cell growth) against the tested human tumor cell lines.
The test results shown in Table 2 indicate that the palla-
dium(II) complexes are more cytotoxic (IC50 = 0.21 –
3.79 µm) than their respective thiosemicarbazone lig-
ands [11, 12, 24]. These results reveal that the metal
chelates exhibit greater antiproliferative activity than
their free ligands, due perhaps to the higher lipophilic
character that favors a facile transport through the cel-
lular membrane. Thus the complex may intercalate
faster between the nitrogen bases of the DNA, pro-
ducing conformational changes in the double helix and
then causing cell death [17, 32, 33].
The Pd(TSC2)2 (6) and Pd(TSC4)2 (8) complexes
show strong cytotoxic activity against all human tumor
cell lines, with IC50 values of 0.28 – 0.67 and 0.21 –
0.99 µM, respectively. On the other hand, the com-
plexes Pd(TSC3)2 (7) and Pd(TSC4)2 (8) are more cy-
totoxic at low micromolar concentrations (IC50 = 0.69
and 0.21 µM, respectively) against the (K562) human
chronic myelogenous leukemia cell line, when com-
pared to the palladium(II) bis-chelate complexes of
benzaldehyde and o-nitro benzaldehyde thiosemicar-
bazone (IC50 = 6.15 and 3.04 µM, respectively). Prob-
ably, the presence of the o-methoxy and o-cyano sub-
stituents in the benzene ring may be an important fac-
tor in the activity. In addition, the Pd(TSC1)2 (5) and
Pd(TSC2)2 (6) complexes (IC50 = 0.30 and 0.31 µM,
respectively) tested in vitro against the (K562) hu-
man chronic myelogenous leukemia cell line appeared
to be more cytotoxic with respect to other palla-
dium(II) complexes of the acetone Schiff bases of
S-methyl and S-benzyldithiocarbazate (IC50 = 5.84
and 5.00 µM, respectively) assayed in the human T-
lymphoblastic leukemia cell line [34]. Pd(TSC1)2 (5)
and Pd(TSC2)2 (6) (IC50 = 1.05 and 0.29 µM, respec-
tively) tested in vitro against the (HT-29) colon adeno-
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Table 2. IC50 (µM) values of the palladium complexes Pd(TSC1−4)2 (5 – 8) against the different human tumor cell linesa.
Human tumor cell lines Pd(TSC1)2 (5) Pd(TSC2)2 (6) Pd(TSC3)2 (7) Pd(TSC4)2 (8)
Lung large cell carcinoma (H460) 1.23 0.32 3.79 0.99
Prostate carcinoma (DU145) 1.54 0.67 2.02 0.55
Breast adenocarcinoma (MCF-7) 1.15 0.28 1.58 0.42
Amelanotic melanoma (M-14) 1.65 0.46 2.74 0.88
Colon adenocarcinoma (HT-29) 1.05 0.29 1.08 0.34
Chronic myelogenous leukemia (K562) 0.30 0.31 0.69 0.21
a IC50 corresponds to the concentration required to inhibit 50 % of the cell growth when the cells are exposed to the compounds during 48 h.
Each value is the average of two independent experiments.
carcinoma cell line were more cytotoxic with respect
to the nickel(II) complex of 5-methyl-2-furaldehyde
thiosemicarbazone (IC50 = 37 µM) assayed in vitro
and in vivo against the (CaCo-2) mice tumor cell line
[12]. With respect to other nickel(II) and cobalt(II)
bis-chelate complexes of octahedral geometry (ML2)
of tridentate phenanthrenequinone thiosemicarbazone
(O,N,S) ligands (IC50 = 1.92 and 2.04 µM, re-
spectively) assayed in the T47D human breast can-
cer cell line [15], the complex Pd(TSC4)2 (8) as-
sayed in vitro against the MCF-7 human breast ade-
nocarcinoma cell line turned out to be about ten
times more cytotoxic than the nickel(II) and cobalt(II)
complexes.
In summary, we have synthesized the palladium(II)
bis-chelate complexes with ligands derived from furan-
2-carbaldehyde and benzaldehyde thiosemicarbazone.
The molecular structure of Pd(TSC3)2 (7) shows a
square-planar geometry with two deprotonated ligands
coordinated to Pd(II) through the nitrogen and sulfur
atoms in a trans arrangement. The palladium(II) com-
plexes are more cytotoxic at low micromolar concen-
trations compared to the free ligands.
Experimental Section
Materials and measurements
Chemicals were reagent grade. Palladium(II) bis(acet-
ylacetonate), potassium tetrachloropalladate, thiosemicarb-
azide, 4-phenylthiosemicarbazide, furan-2-carbaldehyde, 5-
phenyl-furan-2-carbaldehyde, o−cyano-benzaldehyde, and
o-methoxy-benzaldehyde were purchased from Aldrich.
Melting points were determined on a Büchi melting point
B-545 apparatus. Elemental analyses were determined on a
Fisons-Carlo Erba Elemental Microanalyzer. Infrared spec-
tra were recorded as KBr pellets (4000 – 400 cm−1) on
a Bruker FT-IR IFS 55 Equinox spectrophotometer. NMR
spectra were recorded on a Bruker Avance DRX 300 spec-
trometer in [D6]DMSO operating at 300 and 75.5 MHz (1H,
13C). The chemical shifts were measured in ppm relative to
tetramethylsilane.
Synthesis of the ligands
General method
To a hot solution of 4-phenyl thiosemicarbazide (3.3 g,
20 mmol) or thiosemicarbazide (1.8 g, 20 mmol) in ethanol
(70 mL) or methanol (100 mL) was added dropwise a so-
lution of a furan-2-carbaldehyde derivative (20 mmol) in
50 mL of ethanol, or a solution of a benzaldehyde thiosemi-
carbazone derivative (20 mmol) in 60 mL of methanol dur-
ing 30 min. The mixture was refluxed for 3 – 4 h and stirred
for 24 h at r. t. The solid product was filtered, washed sev-
erals times with cold ethanol and dried in vacuo. The ligand
HTSC2 (2) was obtained as large yellow needles after slow
evaporation of a dichloromethane-methanol mixture. For the
ligand HTSC3 (3), the final reaction mixture was kept in the
refrigerator, and after several days small colorless needles
were obtained. Crystals suitable for X-ray crystallography
were obtained by recrystallization from hot acetone.
4-Phenyl-1-(furan-2-carbaldehyde) thiosemicarbazone,
HTSC1 (1)
Colorless solid. Yield 82 %, m. p. 160 – 162 ◦C. – Anal.
for C12H11N3OS (245.30 g/mol): calcd. C 58.76, H 4.52,
N 17.13, S 13.07; found C 58.81, H 4.64, N 17.26, S 12.91. –
IR (KBr): ν = 3296 (NHPh), 3132 (NH), 1620 (C=N), 925
(C=S) cm−1. – 1H NMR ([D6]DMSO): δ = 6.65 (t, H4, J =
3.3 Hz), 7.08 (d, H3, J = 3.3 Hz), 7.85 (d, H5, J = 3.3 Hz),
7.18 (t, 2Hmeta, NHPh, J = 8.7 Hz), 7.35 (t, 1Hpara, NHPh,
J = 7.5 Hz), 7.57 (d, 2Hortho, NHPh, J = 9.0 Hz), 8.08 (s,
1H, HC=N), 9.86 (s, 1H, NHPh), 11.97 (s, 1H, =N-NH). –
13C NMR ([D6]DMSO): δ = 112.49, 113.26, 145.26, 149.39
(C4,C3,C5,C2; furan ring), 125.49, 128.26, 138.94 (NHPh),
132.92 (HC=N), 175.64 (C=S).
4-Phenyl-1-(5’-phenyl-furan-2-carbaldehyde) thiosemicarb-
azone, HTSC2 (2)
Yellow needles. Yield 62 %, m. p. 178 – 180 ◦C. – Anal.
for C18H15N3OS (321.40 g/mol): calcd. C 67.2, H 4.70,
N 13.07, S 9.98; found C 67.00, H 4.94, N 13.33, S 9.81. –
IR (KBr): ν = 3290 (NHPh), 3159 (NH), 1618 (C=N), 950
(C=S) cm−1. – 1H NMR ([D6]DMSO): δ = 7.16 (dd, H4, J =
3.7 Hz), 7.21 (d, H3, J = 3.7 Hz), 7.24 (m, 4Hmeta, NHPh, J =
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7.8 Hz), 7.60 (d, 2Hpara, NHPh, J = 7.8 Hz), 7.83 (d, 4Hortho,
NHPh, J = 7.8 Hz), 8.10 (s, 1H, HC=N), 9.95 (s, 1H, NHPh),
11.92 (s, 1H, =N-NH). – 13C NMR ([D6]DMSO): δ =
108.54, 115.87, 148.99, 154.83 (C4,C3,C5,C2; furan ring),
125.40, 128.30, 129.52, 139.04 (NHPh), 124.07, 125.41,
128.34, 129.52 (phenyl-furan ring), 132.47 (HC=N); 175.65
(C=S).
o-Methoxy-benzaldehyde thiosemicarbazone, HTSC3 (3)
Colorless crystals. Yield 82 %, m. p. 220 – 222 ◦C. – Anal.
for C9H11N3OS (209.27 g/mol): calcd. C 51.65, H 5.30,
N 20.08, S 15.32; found C 51.75, H 5.50, N 20.10, S 15.04. –
IR (KBr): ν = 3410 (NH2), 3292 (NH), 1600 (C=N), 874
(C=S) cm−1. – 1H NMR ([D6]DMSO): δ = 3.81 (s, 1H,
OCH3), 8.08 (d, 1Hortho, Ph, J = 7.8 Hz), 7.04 (d, 1Hmeta,
Ph, J = 7.8 Hz), 6.95 (t, 1Hmeta, Ph, J = 7.8 Hz), 7.36 (t,
1Hpara, Ph, J = 7.8 Hz), 8.41 (s, 1H, HC=N), 8.14, 7.93 (d,
2H, NH2), 11.42 (s, 1H, =N-NH). – 13C NMR ([D6]DMSO):
δ = 55.68 (OCH3), 157.76, 131.33, 126.56, 122.18, 120.56,
111.64 (Ph), 137.93 (HC=N), 177.86 (C=S).
o-Cyano-benzaldehyde thiosemicarbazone, HTSC4 (4)
Colorless solid. Yield 90 %, m. p. 210 – 212 ◦C. – Anal.
for C9H8N4S (204,25 g/mol): calcd. C 52.92, H 3.95,
N 27.43, S 15.70; found: C 52.83, H 4.05, N 27.19, S 14.85. –
IR (KBr): ν = 3377 (NH2), 3238 (NH), 2222 (C≡N), 1615
(C=N), 854 (C=S) cm−1. – 1H NMR ([D6]DMSO): δ =
8.23 (d, 1Hortho, Ph, J = 8.0 Hz), 7.86 (d, 1Hmeta, Ph, J =
8.0 Hz), 7.71 (t, 1Hmeta, Ph, J = 8.0 Hz), 7.55 (t, 1Hpara,
Ph, J = 8.0 Hz); 8.34 (s, 1H, HC=N), 8.47, 7.95 (d, 2H,
NH2), 11.79 (s, 1H, =N-NH). – 13C NMR ([D6]DMSO):
δ = 117.78 (C≡N), 136.71, 133.66, 133.29, 129.95, 127.55,
109.57 (Ph), 137.72 (HC=N); 178.64 (C=S).
Synthesis of the palladium(II) complexes
General method
A solution of Pd(acac)2 (0.153 g, 0.5 mmol) in acetone-
ethanol (2 : 1, 90 mL), or a solution of K2PdCl4 (0.163 g,
0.5 mmol) in water-ethanol (2 : 1, 30 mL) was added drop-
wise to a stirred hot solution of the 2-furaldehyde thiosemi-
carbazone derivate (1.0 mmol) in 80 mL of acetone-ethanol
or of the benzaldehyde thiosemicarbazone derivate in ethanol
(60 mL). Sodium acetate (0.082 g, 1 mmol) in 5 mL of wa-
ter was then added. The solution was refluxed for 2 – 3 h and
stirred for 24 h at r. t. The precipitate was collected by fil-
tration, washed three times with cold ethanol (50 mL) and
dried under vacuum. For the complex Pd(TSC3)2 (7), crys-
tals suitable for X-ray crystallography were obtained by slow
evaporation from an acetone solution at r. t. after two weeks.
Bis(4-phenyl-1-(furan-2-carbaldehyde) thiosemicarbazo-
nato)palladium(II), Pd(TSC1)2 (5)
Square-shaped red crystals. Yield 53 %, m. p. 235 –
236 ◦C. – IR (KBr): ν = 3415 (NH2), 1604 (C=N), 880
(C=S) cm−1. – 1H NMR ([D6]DMSO): δ = 6.70 (dd, 2H3),
6.74 (dd, 2H4), 7.95 (d, 2 H5), 7.09 (t, 4Hmeta, NHPh), 7.35
(t, 2Hpara, NHPh), 7.52 (dd, 4Hortho, NHPh), 8.01 (s, 2H,
HC=N), 9.86 (s, 2H, NHPh).
Bis(4-phenyl-1-(5′-phenyl furan-2-carbaldehyde) thiosemi-
carbazonato)palladium(II), Pd(TSC2)2 (6)
Red solid. Yield 66 %, m. p. 284 – 285 ◦C. – IR (KBr):
ν = 3421 (NH2), 1601 (C=N), 910 (C=S) cm−1. – 1H
NMR ([D6]DMSO): δ = 6.87 (t, 2H4), 6.98 (d, 2 H3); 7.13,
7.06 (m, 10 H, 5-phenyl-furaldehyde ring), 7.19 (t, 4Hmeta,
NHPh), 7.38 (t, 2Hpara, NHPh), 7.85 (d, 4Hortho, NHPh),
7.89 (s, 2H, HC=N), 9.54 (s, 2H, NHPh).
Bis(o-methoxy-benzaldehyde thiosemicarbazonato)-
palladium(II), Pd(TSC3)2 (7)
Needle-shaped orange crystals. Yield 55 %, m. p.
> 251 ◦C (decomp.). – IR (KBr): ν = 3375 (NH2), 1585
(C=N), 847 (C=S) cm−1. – 1H NMR ([D6]DMSO): δ =
3.84 (s, 1H, OCH3), 8.71 (d, 2Hortho, Ph), 7.09 (d, 2Hmeta,
Ph), 6.95 (t, 2Hmeta, Ph), 7.42 (t, 2Hpara, Ph), 7.77 (s, 2H,
HC=N), 7.13 (s, 4H, NH2). – 13C NMR ([D6]DMSO):
δ = 56.03, 55.59 (OCH3); 158.43, 158.36, 133.05, 132.51,
132.46, 120.49, 120.07, 119.99, 111.14, 111.02 (Ph), 148.59,
143.99 (HC=N), 176.81, 174.51 (C=S).
Bis(o-cyano benzaldehyde thiosemicarbazonato)-
palladium(II), Pd(TSC4)2 (8)
Orange solid. Yield 48 %, m. p. > 240 ◦C (decomp.). –
IR (KBr): ν = 3419 (NH2), 2216 (C≡N), 1590 (C=N), 815
(C=S) cm−1. – 1H NMR ([D6]DMSO): δ = 8.63, 7.60, 7.23
(m, Ph), 8.96 (s, 2H, HC=N), 8.19 (s, 4H, NH2). – 13C NMR
([D6]DMSO): δ = 119.69, 118.06 (C≡N), 153.13, 152.23,
135.99, 134.35, 133.82, 128.25, 126.95, 124.78, 104.96 (Ph),
143.78 (HC=N), 163.92 (C=S).
Crystal structure determination
The intensities were measured on a Stoe IPDS1 diffrac-
tometer and were corrected for Lorentz and polarization ef-
fects, and for absorption using the program DIFABS [35].
The relevant crystallographic data are listed in the Table 3.
The structure was solved by Direct Methods, and refined with
full-matrix least-squares procedures using SHELX-97 [36].
CCDC 777497 contains the supplementary crystallo-
graphic data for this paper. These data can be obtained free
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Table 3. Crystal data and parameters pertinent to data collec-










β , deg 110.923(9)
Volume, Å3 2079.0(3)
Z 4
Density, g cm−3 1.67
Absorption coeff., mm−1 1.1
θ range for data collect., deg 2.5 – 26.0
Index range hkl ±19, ±12, ±16
Reflections collected 8055
Independent refl. / Rint 1964 / 0.0291
Max. / min. transmission 0.7297 / 0.8962
Data / ref. parameters 1964 / 173
Final R indices R1 / wR2 [I ≥ 2 σ (I)] 0.0175 / 0.0419
R indices R1 / wR2 (all data) 0.0291 / 0.0427
Goodness-of-fit on F2 0.850
Lgst. diff. peak / hole, e Å−3 0.26 /−0.38




The H460 (human lung large cell carcinoma), M-14 (hu-
man amelanotic melanoma), DU145 (human prostate car-
cinoma), MCF-7 (human breast adenocarcinoma), HT-29
(human colon adenocarcinoma), and K562 (human chronic
myelogenous leukemia) cell lines were obtained from the re-
search laboratory of the Faculty of Sciences and Philosophy,
Universidad Peruana Cayetano Heredia. Cells were cultured
in DMEM medium supplemented with 10 % fetal calf serum
and 50 µg mL−1 gentamycin at 37 ◦C in 5 % CO2 / 95 % air.
Assessment of cytotoxicity
Growth inhibition was evaluated by preparing serial di-
lutions in DMSO of the ligands or palladium(II) complexes
(100 – 0.10 µM) and incubating the cells in 96-well plates in
the presence or absence of these fractions for 48 h at 37 ◦C.
The percent of inhibition of cell growth relative to the con-
trol essay was evaluated colorimetrically using the sulforho-
damine B dye, according to a published procedure, with com-
parison to the control [37]. The IC50 value was defined as the
concentration of a test sample resulting in a 50 % reduction
of absorbance as compared with untreated controls that re-
ceived a serial dilution of the solvent in which the test sam-
ples were dissolved, and was determined by linear regression
analysis.
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